Maintain DHR at 70-75% benchmark weight with $195 hard stop through Q3 2026 catalyst; reject Underweight drift
The HOLD rating at 70-75% benchmark weight reflects binding constraints from prior lessons: (1) 8/31 lesson prohibits Underweight into quality compounders with intact FCF — DHR's $4.33B TTM FCF, 32% EBITDA margins, 0.80 defensive beta, and multi-decade DBS integration track record are franchise characteristics that must be protected; (2) 9/04 lesson prohibits split-the-difference execution — the -0.6% alpha failure from 35% trim + 5-10% hedge is directly on-point; (3) 9/11 success (+2.0% alpha) validates that sizing discipline itself is the alpha source on this exact setup. The bear case is analytically correct on the math (H1 2026 $2.68 actuals annualizing to $5.36 vs. $9.30 consensus requiring H2 to nearly double; net debt +61% QoQ to $22.2B; goodwill+intangibles at 74% of assets) and justifies the existing 25-30% trim already executed — but does NOT justify additional Underweight drift when franchise quality remains intact and $195 provides a disciplined invalidation level below the $199-202 structural support cluster.
| Position | Action |
|---|---|
| Current position post-cumulative trims (~70-75% benchmark weight) | Hold and maintain current exposure — sizing discipline is the protective lever, not additional trimming or hedges |
| Close below $195 on any day | Hard stop — exit position entirely, no hedge leg |
| Close above $215 on rising volume (>5M shares) with MACD histogram turning positive AND Q3/Q4 2026 print showing organic EPS run-rate $7.50+ AND integration synergy confirmation AND 10-year yield sustained below 4.5% | Re-engage to full benchmark weight |
| Any 2 of 4 re-engagement triggers fire | Begin scaling back toward full weight incrementally |
| Any Underweight proposal (e.g., 50-60% benchmark weight target with additional trimming) | Reject — violates 8/31 binding constraint against Underweight into quality compounders with intact FCF |
DHR's 66% implied earnings recovery, best-in-class 32% EBITDA margins, and DBS operating moat make this a compelling entry point at 21.9x forward earnings with a PEG of 1.2, as the Q2 2026 acquisition and bioprocessing tailwinds provide multi-year catalysts that the market is currently ignoring.
| Indicator | Value | Signal |
|---|---|---|
| close | $203.25 | neutral |
| close_10_ema | $205.54 | bearish |
| close_50_sma | $202.49 | neutral |
| close_200_sma | $201.75 | neutral |
| rsi | 46.25 | neutral |
| macd | 0.06 | bearish |
| macds | 1.96 | bearish |
| macdh | -1.90 | bearish |
| boll_middle | $209.49 | neutral |
| boll_upper | $222.00 | neutral |
| boll_lower | $196.98 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Daily close above $215 on rising volume (>5M shares) with MACD histogram turning positive
Then: Momentum reset signal — first trigger for re-engagement pathway
↩ rebuts: “Bear claim that the acquisition represents dangerous leverage”
EV: ~14% upside from $203.25 to $232 · concedes: Lagged S&P 500 by ~8 percentage points over last six months; 5-year total return: -26.6%; MACD just crossed bearishly; Stock wedged below 10 EMA and VWMA; Net Debt/EBITDA elevated at ~1.72x historically; Polymarket 94% probability on zero Fed cuts in 2026
A well-run business with broken price action, bloated leverage, a macro headwind pressing on its valuation, and forward estimates that require mathematical miracles to hit is a SELL, not a BUY.
EV: -$190 stock if $200 fails (bear view) · concedes: EPS trajectory is improving; 32% EBITDA margins are best-in-class; DBS is a real operating system; DHR is not a poorly-run business; Net Debt/EBITDA at 1.72x is 'manageable' in absolute terms; Institutional sponsorship is intact (retention story, not momentum story); MACD bearish cross could be invalidated by daily close above $215 on rising volume
→ vs conservative: Quality moat (32% EBITDA margins, Danaher's M&A track record) does not protect against multiple compression when duration trade unwinds and yields push through 5%; the balance sheet is now stretched with 61% net debt increase and 74% goodwill/intangibles versus prior cycles
→ vs neutral: Waiting for $200 confirmation is reactive - the MACD has already crossed down at minus 1.90, price action shows failed rallies at 218.85 twice, and the EPS consensus requiring 147% H2 acceleration is already disprovable mathematically before the guide-down comes
| atr | 5.73 | neutral |
| vwma | $208.56 | bearish |
Support: 200 · 196.98 · 190.48 | Resistance: 205.54 · 209.49 · 215 · 218.85
DHR exhibits a neutral technical profile with a slight bearish lean, as the MACD bearish cross (histogram -1.90), price below the 10 EMA ($205.54), and price below the VWMA ($208.56) all signal short-term selling pressure; however, the RSI at 46.25 remains neutral and the 50 SMA ($202.49) sits just above the 200 SMA ($201.75), keeping the long-term trend technically intact despite a razor-thin margin. Key levels to watch are resistance at $205.54/$209.49/$215-218.85 and support at $200/$196.98/$190.48, with the ATR of $5.73 indicating elevated volatility warranting wider position stops.
Market Cap
$142.88B
P/E (TTM)
36.29
Forward P/E
21.86
PEG Ratio
1.2
P/B
2.72
EPS (TTM)
$5.60
Forward EPS
$9.30
Dividend Yield
0.80%
Beta
0.808
52W High
$242.80
52W Low
$160.93
50-Day MA
$202.38
200-Day MA
$202.39
Revenue FY2022
$26,643M
Revenue FY2023
$23,890M
Revenue FY2024
$23,875M
Revenue FY2025
$24,568M
Revenue TTM
$25,107M
Net Income FY2022
$7,209M
Net Income FY2023
$4,764M
Net Income FY2024
$3,899M
Net Income FY2025
$3,614M
Diluted EPS FY2022
$9.66
Diluted EPS FY2023
$6.38
Diluted EPS FY2024
$5.29
Diluted EPS FY2025
$5.05
Gross Margin TTM
58.8%
Gross Margin FY2022
60.8%
Gross Margin FY2025
59.1%
Operating Margin FY2022
28.3%
Operating Margin FY2025
19.1%
Operating Margin TTM
19.8%
EBITDA TTM
$8,028M
EBITDA Margin TTM
32.0%
Profit Margin TTM
16.0%
ROE TTM
7.61%
ROA TTM
3.95%
Total Assets Q2'26
$92.37B
Total Assets FY2025
$83.46B
Total Debt Q2'26
$26.56B
Net Debt Q2'26
$22.21B
Long-term Debt Q2'26
$25.15B
Goodwill + Intangibles Q2'26
$68.77B
Stockholders' Equity
$52.58B
Current Ratio TTM
1.65
Debt/Equity Q2'26
0.51
Book Value per Share
$74.81
Operating CF FY2025
$6.42B
Free Cash Flow FY2025
$5.26B
FCF Margin
~21%
Capex FY2025
$1.16B
Net Business Purchase Q2'26
$9.84B
Long-term Debt Issuance Q2'26
$6.56B
Net Debt / EBITDA
~1.72x
Working Capital Q2'26
$5.28B
Cash Dividends FY2025
$878M
Share Repurchases FY2025
$3.09B
Share Repurchases FY2024
$5.98B
Strengths
Concerns
Danaher Corporation is a leading healthcare diagnostics and life sciences conglomerate with a market cap of ~$142.88B, currently emerging from a 3-year COVID-related earnings trough with TTM EPS of $5.60 expected to recover to $9.30 by FY2027. A transformative $9.84B acquisition closed in Q2 2026 (financed with $6.56B new debt), pushing Net Debt to $22.21B while adding ~$8B in goodwill and intangibles, though the company's best-in-class 32% EBITDA margin, ~21% FCF margin, and disciplined Danaher Business System provide strong integration execution support. The stock trades at 21.9x forward P/E with a PEG of 1.2 — attractive for a quality compounder — but near-term risks include elevated leverage, integration execution, and potential for uneven quarterly EPS recovery given Q1 2026 softness.
Macro: 10-year U.S. Treasury yield briefly touched a multi-year high above 5% before pulling back; Fed funds rate implied at 94% probability of zero cuts in 2026 (up +1.2pp WoW); US recession probability at 10% (up +3pp WoW); Japan 6%, UK 10%; inflation >4.5% probability at 12% (up +2pp WoW), >5% at 8%; markets repricing from soft-landing to no-landing transition.